§
Luxuse
Patent Intelligence
Sign In
Patent US5569462A successfully refreshed from Google Patents.
← Back to Patent Explorer
US5569462A Expired / Lapsed US ⏱️ 0.0 years remaining

Methods for enhancing vascularization of implant devices

Assignee: Baxter International Inc
•
Filing: 1995-03-31
•
Granted: 1996-10-29
•
Expires: 2015-03-31
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Methods for enhancing vascular support of cells housed within an implanted apparatus are disclosed. The methods comprise placing a population of therapeutic substance-producing cells into the cell receiving chamber of an immunoisolation apparatus, implanting the apparatus into a patient, and administering an immunomodulatory agent to the patient. The immunomodulatory agent increases the number of close vascular structures in the vicinity of the implanted device, which increases the long term survival of the cell population housed therein.

Inventors

  • 👤 Laura A. Martinson
  • 👤 James H. Brauker
  • 👤 Robert C. Johnson
  • 👤 Thomas Loudovaris

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 22:55
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/04; A61K38/12; A61K38/13; A61L; A61L27/00; A61L27/36; A61L27/38; A61P; A61P37/00; A61P37/02; A61P37/06; B; B65; B65D; B65D5/00; B65D5/42; B65D5/4212; Y; Y10; Y10S; Y10S623/00; Y10S623/915

Claims Analysis

Total Claims: 15
Claim 1
Independent Claim 85 words
A method for implanting cells in a patient, comprising the steps of: (a) providing a population of viable cells; (b) implanting into said patient an immunoisolation apparatus having structure defining a cell receiving chamber therein, said immunoisolation apparatus comprising an immunoisolation zone that immunoisolates said cell receiving chamber; (c) placing said population into said cell receiving chamber of said immunoisolation apparatus; and (d) administering an immunomodulatory agent to said patient in an amount and for a time effective to enhance vascularization of said implanted apparatus.
Claim 2
Independent Claim 85 words
A method for implanting cells in a patient, comprising the steps of: (a) providing a population of viable cells; (b) implanting into said patient an immunoisolation apparatus having structure defining a cell receiving chamber therein, said immunoisolation apparatus comprising an immunoisolation zone that immunoisolates said cell receiving chamber; (c) placing said population into said cell receiving chamber of said immunoisolation apparatus; and (d) administering an immunomodulatory agent to said patient in an amount and for a time effective to enhance vascularization of said implanted apparatus.
Claim 3
Dependent Claim 25 words
The method of claim 1, wherein said cell population is placed in said cell receiving chamber after said immunoisolation apparatus is implanted in said patient.
Claim 4
Dependent Claim 18 words
The method of claim 1 wherein said population of viable cells is capable of producing a therapeutic substance.
Claim 5
Dependent Claim 15 words
The method of claim 1, wherein said cell population comprises at least one xenogeneic cell.
Claim 6
Dependent Claim 15 words
The method of claim 1, wherein said cell population comprises at least one allogeneic cell.
Claim 7
Dependent Claim 15 words
The method of claim 1, wherein said cell population comprises at least one isogeneic cell.
Claim 8
Dependent Claim 34 words
The method of claim 3, wherein said cell population comprises at least one cell carrying an extrinsic nucleic acid construct conferring upon said at least one cell the capability of producing said therapeutic substance.
Claim 9
Dependent Claim 13 words
The method of claim 1, wherein said immunomodulatory agent is an antiinflammatory agent.
Claim 10
Dependent Claim 13 words
The method of claim 1, wherein said immunomodulatory agent is an immunosuppressive agent.
Claim 11
Dependent Claim 12 words
The method of claim 1, wherein said immunomodulatory agent is cyclosporine A.
Claim 12
Dependent Claim 18 words
The method of claim 1, said immunoisolation apparatus further comprising means for effecting close vascularization of said apparatus.
Claim 13
Dependent Claim 16 words
The method of claim 11, wherein said means for effecting close vascularization comprises a vascularization zone.
Claim 14
Dependent Claim 20 words
The method of claim 12, wherein said immunoisolation zone is interposed between said vascularizing zone and said cell receiving chamber.
Claim 15
Dependent Claim 35 words
The method of claim 11, wherein said means for effecting close vascularization comprises at least one vascularization cell housed within said cell receiving chamber, said vascularization cell producing an effective amount of a vascularizing substance.

References Cited (Backward Citations)

US3093831A Cited
US3313289A Cited
US3967618A Cited
US3646616A Cited
US3699956A Cited
US4069307A Cited
US4011861A Cited
US3993072A Cited
US4936317A Cited
US4374669A Cited
US4180560A Cited
US4192308A Cited
US4306318A Cited
US4207390A Cited
US4217664A Cited
US4352883A Cited
US4391909A Cited
US4266999A Cited
US4298002A Cited
US4309996A Cited
US4309776A Cited
US4368737A Cited
US4576608A Cited
US4353888A Cited
US4557724A Cited
US4553272A Cited
US4413359A Cited
US4378016A Cited
US4352888A Cited
US4542539A Cited
US4475916A Cited
WO1983003536A1 Cited
US4505277A Cited
US4664669A Cited
CA1196862A Cited
EP0127989A2 Cited
US4673566A Cited
US4689293A Cited
US4806355A Cited
US4803168A Cited
US4670286A Cited
US4601893A Cited
US4508113A Cited
US4684524A Cited
US4657544A Cited
US4686098A Cited
US4681582A Cited
US4687481A Cited
US4597765A Cited
EP0188309A2 Cited
US4685447A Cited
US4624847A Cited
US4712553A Cited
EP0213908A2 Cited
EP0232543A2 Cited
US4743252A Cited
GB2185408A Cited
US4723947A Cited
US4871366A Cited
US4804381A Cited
US4798585A Cited
EP0259536A2 Cited
US4880006A Cited
EP0277678A1 Cited
US4877029A Cited
US4816339A Cited
US4826480A Cited
US4871542A Cited
US4795459A Cited
US4911717A Cited
US4878913A Cited
US5077215A Cited
US4922926A Cited
US4892538A Cited
US4855141A Cited
US4950483A Cited
US5011472A Cited
US5219361A Cited
EP0359575A2 Cited
US4878895A Cited
DE8813531U1 Cited
EP0370292A1 Cited
DE4006145A1 Cited
US4990138A Cited
US5015476A Cited
US4937196A Cited
US5002661A Cited
US5112614A Cited
US5024670A Cited
US5100392A Cited
US5324518A Cited
US5156623A Cited
US5201728A Cited
US5326568A Cited
US5344454A Cited
US5213574A Cited
US5262055A Cited
JPH0878845A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1999-10-29 2000-04-29 2000-10-29 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2003-10-29 2004-04-29 2004-10-29 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2007-10-29 2008-04-29 2008-10-29 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag